Related Experiment Video
Updated: Jun 3, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
Clinical Variant of Serpentine Supravenous Hyperpigmentation Following Subcutaneous Bortezomib Injection
Madelyn Richards1, Stephen E Weis1,2
1University of North Texas Health Science Center at Fort Worth, Fort Worth, TX.
HCA Healthcare Journal of Medicine
|January 10, 2025
Summary
This study reports a rare case of serpentine supravenous hyperpigmentation (SSH) in a multiple myeloma patient treated with subcutaneous bortezomib. This unique finding highlights a previously undocumented cutaneous reaction to this chemotherapy administration route.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Bortezomib is a proteasome inhibitor used for multiple myeloma.
- It can be administered intravenously or subcutaneously.
- Subcutaneous administration offers similar efficacy with fewer side effects.
Observation:
- This paper details a rare case of serpentine supravenous hyperpigmentation (SSH).
- SSH occurred after subcutaneous bortezomib administration.
- This reaction has not been previously reported with subcutaneous chemotherapy.
Findings:
- This is the first reported case of SSH following subcutaneous bortezomib.
- Bortezomib is not commonly associated with SSH.
- Subcutaneous administration of chemotherapeutic agents has not previously been linked to SSH.
Implications:
- This case expands the known spectrum of bortezomib-induced cutaneous reactions.
- It suggests that subcutaneous chemotherapy can also cause SSH.
- Further investigation into the mechanisms of SSH with different administration routes is warranted.
